Jazz Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jazz Pharmaceuticals (JAZZ).

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

18Buy

2Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$263Upside to Avg. PT+13.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$325
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$337
Sep 11, 2026	UBS	Ashwani Verma	PT Raise	Buy	$315→$337
Sep 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$270→$271
Aug 26, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$287→$300
Aug 26, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$283→$322
Aug 26, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$264→$281
Aug 26, 2026	Needham	Ami Fadia	PT Raise	Buy	$292→$310
Aug 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$280→$283
Aug 4, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$265→$276
Aug 4, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$254→$264
Aug 4, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$275→$300
Aug 4, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$301→$310
Aug 4, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$285→$300
Aug 4, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$245→$280
Aug 4, 2026	Needham	Ami Fadia	PT Raise	Buy	$282→$292
Aug 4, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$260→$270
Aug 4, 2026	Baird	Joel Beatty	PT Raise	Outperform	$252→$280
Jul 20, 2026	Needham	Ami Fadia	PT Raise	Buy	$255→$282
Jul 17, 2026	Canaccord Genuity	Gary Nachman	Initiate	Buy	$290

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and announces $337 price target.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

UBS analyst Ashwani Verma maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $315 to $337.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $270 to $271.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.

Benzinga Newsdesk

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.

Avi Kapoor

Jazz Pharmaceuticals PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Jazz Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

People Also Watch

People Also Watch

Jazz Pharmaceuticals PLC

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Jazz Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PROUBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PROBarclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

PRODeutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

PROMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

People Also Watch

People Also Watch

PRO
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

PRO
UBS Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $337

PRO
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $271

PRO
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

PRO
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322